TCRX:NASDAQTScan Therapeutics, Inc. Analysis

TScan Therapeutics, Inc. trades at $0.3179, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. The last 30 days have lost 57.1%. RSI sits at 17.8, which reads as oversold, and MACD momentum is bearish. The recent range runs from support at $0.3100 up to resistance at $0.8380.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 738.8% above today's level. Revenue is contracting at 65.8%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 173.2%, a beta of 1.48 and a maximum drawdown of 87.4%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.